Synthetic Oncolytic LNP-Replicon RNA for Cancer Immunotherapy
Exclusively Licensed
Invention type: Technology
/
Case number: #21306HJQ
The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.
Researchers
Darrell J Irvine
/
Noor Momin
/
Yingzhong Li
/
Yizhou Dong
/
Ron Weiss
/
Karl Dane Wittrup
Departments: Department of Biological Engineering, Department of Chemical Engineering
Technology Areas: Biotechnology: Synthetic Biology / Drug Delivery: Microparticles & Nanoparticles / Therapeutics: Nucleic Acids, Vaccines
Impact Areas: Healthy Living
-
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Hong Kong | Published application -
synthetic oncolytic lnp-replicon rna for cancer immunotherapy
United States of America | Granted | 11,717,548 -
synthetic oncolytic lnp-replicon rna uses for cancer immunotherapy
United States of America | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
European Patent Convention | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
New Zealand | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
United States of America | Granted | 12,383,589 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Philippines | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Korea (south) | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Malaysia | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Australia | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Brazil | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Canada | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
China | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Colombia | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
European Patent Convention | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Israel | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
India | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Japan | Granted | 7,561,134 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Mexico | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Malaysia | Granted | 0 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
New Zealand | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Philippines | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Russian Federation | Granted | 2,809,724 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Saudi Arabia | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Singapore | Granted | 11,202,109,514 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Thailand | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Korea (south) | Granted | 10 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
United Arab Emirates | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Japan | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Malaysia | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Germany | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
France | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
United Kingdom | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Italy | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Spain | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Netherlands | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Switzerland | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Belgium | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Austria | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Denmark | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Sweden | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Ireland | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Norway | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Poland | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Portugal | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Finland | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Czech Republic | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Hungary | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Greece | Granted | 3,934,673 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
China | Pending
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.